Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004)

作者：Dalong Yang, Yi-He Yan, Yongrong Lai, Ming-Song Wu, Xiao-Feng Dong, Yao-Zhi Chen, Wenfeng Li, Fuquan Yang, Yong‐Yu Yang, Teng-Meng Zhong, Guo‐Dong Wang, Qingqing Pang, Kang Chen, Ning Peng, Jun-Liang Nong, Ze Su, Yaqun Yu, Lin Ye, Fan-Jian Zeng, Shaoping Liu, Xueyao Wang, Hongbing Yao, Chuang Qin, Yingyu Zhang, Jie Liu, Mian-Jing Li, Yong-Rong Liang, Pei‐Sheng Wu, Fu-Xin Li, X H Mao, Shuchang Chen, Jun‐Jie Ou, Min Luo, Sicong Lu, Zhicheng Li, Shen Huang, Jia‐Yong Su, Huan Chen, Yi-Ge Zhang, Xiumei Liang, Yi-Li Ma, Liang Ma, Jian‐Hong Zhong · 发表于：JHEP Reports · 年份：2025 · DOI：10.1016/j.jhepr.2025.101587 · 被引用次数：7 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Inflammatory Biomarkers in Disease Prognosis、Cholangiocarcinoma and Gallbladder Cancer Studies

Background & aims It is unclear whether radiological complete response (rCR) and pathological complete response (pCR) after immune-based conversion therapy are associated with each other and with the prognosis of patients with initially unresectable hepatocellular carcinoma (uHCC). Methods Data were retrospectively analyzed from 1,262 patients with uHCC who received immune-based conversion therapy at 22 medical centers across China between 2019 and 2023. Survival was compared among patients showing different responses through conventional analysis of all patients, conventional analysis of propensity score-matched subgroups, and landmark analyses at 5 and 7 months after treatment. Results Conversion therapy led to tumor downstaging in 343 patients (27.2%) and upstaging in 91 (7.2%) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. The 254 patients who achieved rCR showed significantly better overall survival at 3 years than the 1,008 who did not (79.4% vs. 34.0%), as well as significantly longer progression-free survival (hazard ratio [HR] 0.22, 95% confidence interval 0.19–0.26). These survival benefits were confirmed in landmark analyses at 5 and 7 months and in propensity score-matched subgroups. pCR was associated with better overall survival (HR 0.29) and recurrence-free survival (HR 0.40). Among those undergoing hepatectomy after conversion therapy, rCR was strongly associated with higher pCR rates (67.1% vs. 13.8% in non-rCR patients; Φ ...